Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation

Bristol Myers’ $800M bispecific ADC aces China breast cancer study, putting TROP2 drugs on notice

Regeneron pens $2.3B pact with Parabilis to develop new type of ADC-like therapy

Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals